Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PT Metro Healthcare Indonesia Tbk's Debt-to-EBITDA or its related term are showing as below:
ISX:CARE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -787.9 Med: -13.41 Max: 36.52
Current: 9.83
During the past 10 years, the highest Debt-to-EBITDA Ratio of PT Metro Healthcare Indonesia Tbk was 36.52. The lowest was -787.90. And the median was -13.41.
ISX:CARE's Debt-to-EBITDA is ranked worse than 89.75% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs ISX:CARE: 9.83
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PT Metro Healthcare Indonesia Tbk Debt-to-EBITDA Related Terms
PT Metro Healthcare Indonesia Tbk Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Metro Healthcare Indonesia Tbk Debt-to-EBITDA Chart
ISX:CARE vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, PT Metro Healthcare Indonesia Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Metro Healthcare Indonesia Tbk Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Metro Healthcare Indonesia Tbk's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Metro Healthcare Indonesia Tbk's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
PT Metro Healthcare Indonesia Tbk (ISX:CARE) has a Debt-to-EBITDA of 9.26 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Metro Healthcare Indonesia Tbk. According to the industry distribution chart, PT Metro Healthcare Indonesia Tbk ranks #429 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 89.7%.
Is PT Metro Healthcare Indonesia Tbk's Debt-to-EBITDA too high?
PT Metro Healthcare Indonesia Tbk's current Debt-to-EBITDA is 9.26. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. PT Metro Healthcare Indonesia Tbk's value of 9.26 is 321.9% above this industry median. Based on the distribution chart, PT Metro Healthcare Indonesia Tbk ranks #429 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PT Metro Healthcare Indonesia Tbk has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Metro Healthcare Indonesia Tbk's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Metro Healthcare Indonesia Tbk ranks #429 out of 478 companies for Debt-to-EBITDA. This places PT Metro Healthcare Indonesia Tbk in the lower half of its industry. The industry median Debt-to-EBITDA is 2.20. PT Metro Healthcare Indonesia Tbk's value of 9.26 is 321.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Metro Healthcare Indonesia Tbk's current Debt-to-EBITDA of 9.26 is 321.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Metro Healthcare Indonesia Tbk. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Metro Healthcare Indonesia Tbk's current Debt-to-EBITDA is 9.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Metro Healthcare Indonesia Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Metro Healthcare Indonesia Tbk (ISX:CARE) is currently considered Modestly Overvalued. The stock's GF Value™ is Rp366.26, compared to a current price of Rp440.00 — trading 20.1% above its estimated fair value. The current Debt-to-EBITDA is 9.26 and 321.9% above the Healthcare Providers & Services industry median of 2.20. PT Metro Healthcare Indonesia Tbk's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PT Metro Healthcare Indonesia Tbk (ISX:CARE), the current Debt-to-EBITDA is 9.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Metro Healthcare Indonesia Tbk (ISX:CARE) Overvalued in 2026?
Based on GuruFocus' analysis, PT Metro Healthcare Indonesia Tbk stock appears to be overvalued.
The current stock price of Rp440.00 is trading 20.1% above its estimated GF Value™ of Rp366.26.
GuruFocus considers PT Metro Healthcare Indonesia Tbk to be Modestly Overvalued.
Key valuation signals for ISX:CARE:
Debt-to-EBITDA: 9.26
GF Value™: Rp366.26 vs. price of Rp440.00 (20.1% above fair value)
Industry Position: 321.9% above the Healthcare Providers & Services median (#429 of 478)
No single metric tells the full story. See the ISX:CARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Metro Healthcare Indonesia Tbk provides integrated health services that consist of hospital and technology-based health services and training centers to produce professionals in health services. The company manages hospitals that are members of the Metro Hospital Group. Its business segment comprises Hospital services and Investment. The majority of revenue is derived from the Hospital services segment that comprises integrated healthcare services for inpatient and outpatient.
71GF Score
Get the complete analysis for ISX:CARE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:CARE has been successfully added to your 
